Nuveen Asset Management, LLC Zymeworks Inc. Transaction History

Nuveen Asset Management, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$4.82 - $7.7 $175,072 - $279,679	-36,322 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$6.0 - $16.98 $18,048 - $51,075	3,008 Added 9.03%	36,322 $254,000
Q4 2021 Feb 14, 2022	BUY	$15.19 - $29.33 $506,039 - $977,099	33,314 New	33,314 $546,000
Q3 2021 Nov 12, 2021	SELL	$27.35 - $37.28 $1.92 Million - $2.62 Million	-70,351 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$26.5 - $38.23 $1.86 Million - $2.69 Million	70,351 New	70,351 $2.44 Million
Q1 2021 May 17, 2021	SELL	$29.83 - $56.81 $643,612 - $1.23 Million	-21,576 Closed	0 $0
Q4 2020 May 17, 2021	SELL	$39.12 - $54.99 $844,053 - $1.19 Million	-21,576 Reduced 50.0%	21,576 $1.02 Million
Q4 2020 Feb 16, 2021	BUY	$39.12 - $54.99 $1.05 Million - $1.47 Million	26,732 Added 162.8%	43,152 $2.04 Million
Q3 2020 Nov 16, 2020	SELL	$29.21 - $46.58 $838,502 - $1.34 Million	-28,706 Reduced 63.61%	16,420 $765,000
Q2 2020 Aug 14, 2020	SELL	$33.67 - $40.0 $1.29 Million - $1.53 Million	-38,165 Reduced 45.82%	45,126 $1.63 Million
Q1 2020 May 14, 2020	BUY	$24.28 - $49.8 $2.02 Million - $4.15 Million	83,291 New	83,291 $2.95 Million

296K

Ticker ZYME
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,694,400
Market Cap $872M
Description
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas...

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Nuveen Asset Management, LLC with notifications on news.